Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL: Who Reports Side Effects? Age, Gender & Country Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

Gender Distribution

25.3%
Female
74.7%
Male

Age Information

The average age of patients reporting adverse events with COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL is 46.2 years.

Geographic Distribution

The majority of adverse event reports for COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL originate from US.

Report Summary & Outcomes

8,432
Total Reports
8,432
As Primary/Secondary Suspect
131
Deaths Reported
647
Hospitalizations
33
Life-Threatening
27
Disabilities

Reporting Timeline

First adverse event report: 1993. Most recent report: 20250115. View full timeline →

More About COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL

COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL Full Profile Reports by Year Drug Interactions